RNA Therapeutics Conference

Investigating the next generation of genetic medicine through RNA based therapies

February 8-9, 2023- London, United Kingdom

We are proud to announce the 14th Annual RNA Therapeutics Conference taking place on 8-9 February 2023

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. With Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.

In 2023, we will see the return of our RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

Don't miss this opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

Benefits of Attending

  • Explore how mRNA is leading the way in the genetic medicine space as the next generation of novel drug modalities
  • Investigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics
  • Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH
  • Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases

Who should attend

Pharma and Biotech Directors, Managers and Heads of Departments of:
  • RNA
  • Genetic Medicine
  • Oligonucleotide Discovery
  • RNA Discovery
  • New Modalities
  • RNA Biology
  • RNA Formulation and Delivery
  • Targeted Delivery
  • Clinical Development
  • Pre-Clinical Development
  • Oligonucleotide Chemistry
  • Drug Discovery
  • Target Discovery
  • Medicinal Chemistry
  • RNA Development
  • RNA Vaccines
  • RNA Biochemistry


  • Arun Kumar, Preclinical Lead Vaccine Development, Coalition for Epidemic Preparedness Innovations (CEPI)
  • Christian Plank, Chief Technology Officer, Ethris GmbH
  • Covadonga Paneda, Chief Development Officer, Altamira Therapeutics
  • Daniel Tondera, Head of Biology, Pantherna Therapeutics GmbH
  • Dmitry Samarsky, Chief Technology Officer, Sirnaomics, Inc
  • Ekkehard Leberer, Life Sciences Consultant, Elbicon
  • Heinrich Haas, VP Formulation & Drug Delivery, BioNTech
  • Jimmy Weterings, Senior Director, Technology Innovation, Sirnaomics, Inc
  • Joseph Martinelli, Executive Director, Eli Lilly
  • Lykke Pedersen, Head of RNA Therapeutics, Abzu Aps
  • Martin Akerman, Chief Technical Officer, Envisagenics
  • Nicole Datson, Chief Development Officer, Vico Therapeutics
  • Oliver Ernst, Managing Director, NEUWAY Pharma GmbH
  • Rok Sekirnik, Head of Process Development, mRNA pDNA, BIA Separatio
  • Samir Ounzain, CEO, HAYA Therapeutics
  • Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
  • Souphalone Luangsay, Senior Principal Scientist, F. Hoffmann-La Roche Ltd
  • Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Venkatesh Pilla Reddy, Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
  • Virginia Castilla-Llorente, Associate Director, Evox Therapeutics Ltd
  • Yaniv Erlich, CEO, Eleven Therapeutics
  • Ying Yu, Associate Director, AbbVie

Please fill in your name and email to receive the Conference Agenda of this event.


Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK

Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Physical Event
Reference :ASDE-23957

Available in the same serie

Other interesting Biomarker / Molecular Diagnostics / Enzymes events